Biomedical subjects

Anna Woźniacka

Publications and source records attributed to Anna Woźniacka.

11 recordsLinked to original sources

PubMed2005

[Chloroquine influence on lipid metabolism and selected laboratory parameters].

Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease with complex pathogenesis, various clinical presentation and chronic course with relapses. Mode of treatment depends on the disease activity and kind of internal organ involvement. In most cases clinical remission could be obtained after antimalarials, nonsteroidal anti-inflammatory drugs, corticosteroids, and photoprotection use. Despite the approved antimalarials therapeutic value, the mechanisms by which they provide benefit in lupus, patients are not fully understood. Literature data indicate that they can influence lipid metabolism. The aim of the performed study was the objective evaluation of the influence of 3-month chloroquine treatment (Arechin, 250 mg/day) on lipid metabolism and selected laboratory parameters. In 34 patients with SLE clinical and laboratory evaluation was performed twice, before and after 3-month treatment. After 3 months significantly lower total cholesterol level was observed (mean value 184.91 mg%, 165.26 mg%, p < 0.001). Also LDL level was evidently lowered (111.27 mg%, 99.25 mg%). Similar tendency was noticed in triglycerides, which level after 3 months decreased from the average 152.38 mg% to 104.97 mg%, p < 0.001. Moreover the lowering of sedimentation rate, increasing hemoglobin level and lengthening coagulation time was perceived. The results of the study indicate the influence of chloroquine on decreasing of the disease activity, its anti-inflammatory properties and mainly the drug impact on lipid metabolism. Not only does antimalarials treatment reduce the risk of atherosclerosis development but it also minimizes corticosteroids side effects, which are considered to be the basic medication in lupus patients.

Adult↗

PubMed2004

Multiple myeloma in a patient with systemic lupus erythematosus, myasthenia gravis and non-familial diffuse palmoplantar keratoderma.

The coexistence of autoimmune diseases and malignancies including lymphoproliferative diseases is often reported in the literature. Here we report an unusual case with two autoimmune diseases--myasthenia gravis (MG) and systemic lupus erythematosus (SLE) associated with unique palmoplantar keratoderma (PK) which preceded the development of multiple myeloma (MM) for twenty and seven years respectively. MG associated with non-malignant thymoma developed in 1981 and was successfully treated with thymectomy and physostigmine. Thirteen years later SLE was diagnosed and until now it is also accompanied by skin lesions corresponding to non-familial, diffuse palmoplantar keratoderma which is resistant to treatment. In 2001 the patient revealed inguinal and abdominal lymphadenopathy first diagnosed as extramedullary plasmacytoma and then as multiple myeloma on the basis of bone marrow infiltration and monoclonal gammopathy. Therapy with VAD regimen achieved complete remission of the MM and significant improvement of the skin changes lasting for six months. We failed to collect sufficient numbers of CD 34+ cells for peripheral blood stem cell transplantation. Now the malignancy is in partial remission after CHOP therapy and the skin lesions have returned to their initial status. To our knowledge, this is the first case to be reported with coexistence of these four diseases.

Adult↗

PubMed2004

The distribution of peripheral blood dendritic cells assayed by a new panel of anti-BDCA monoclonal antibodies in healthy representatives of the polish population.

A growing number of studies are being performed on the role of dendritic cells (DCs) in the etiopathogenesis of various conditions. Therefore, it is extremely important to establish the best comparable methods for the determination of the absolute count of blood dendritic cells (BDCs) or their subsets, and the reference normal values for comparisons. The aim of our study was to assess a normal profile of BDCs in the non-cultured human blood of healthy Polish volunteers. BDCs were detected among peripheral blood mononuclear cells (PBMC) from 99 healthy people, aged 18-56. Based on the panel of novel anti-BDCA1, BDCA2 and BDCA3 monoclonal antibodies (MoAbs), three main subpopulations of BDCs were distinguished: two myeloid types of BDCs, MDC1(BDCA-1+/ CD11c+ /HLA-DR+) or MDC2 (BDCA-3+/CD32-/CD64-/HLA-DR+), and a plasmacytoid subtype, PDC (BDCA-2+/CD123+/HLA-DR+). The number and percentage of BDCs were correlated with the age, gender, photosensitivity (phototype, minimal erythemal dose -- MED) and morphological parameters of the healthy volunteers. BDCs represented 0.83% of the PBMC and the median total BDC number was 44.0 cell/microl. The total BDC number correlated with the WBC count (rho=0.40, p=0.001) as well as with the lymphocyte and monocyte counts (rho=0.20, p=0.045 and rho=0.26, p=0.009, respectively). The median percentage of the MDC1 count (0.20%) was twice as high as the MDC2 count (0.10%). The median PDC count was 28.2 cell/microl, and these cells represented 0.50% of the PBMC. There was a positive correlation between PDC and skin photosensitivity (rho=0.28, p=0.005). An inverse correlation between the PDC count and the age of the examined volunteers was also found (rho=-0.22, p=0.029). Our study provides the first referential data on normal rates and counts of BDCs and their subpopulations, assessed by the new panel of anti-BDCA MoAbs, in healthy Polish subjects. The method used in the study allowed the determination of BDCs and their subset numbers in a relatively small blood volume.

Adult↗

PubMed2004

[Cutaneous lupus--current problem in dermatology].

A case of lupus vulgaris in 83-year-old woman is presented. Skin lesions appeared 20 years earlier and till now were not treated. Cutaneous tuberculosis is a particular form of infection caused by Mycobacterium tuberculosis. Until recently tuberculosis occurred infected with human immunodeficiency virus a greater incidence of cutaneous tuberculosis is being observed.

Aged↗

PubMed2003

Cryotherapy in the treatment of angiolymphoid hyperplasia with eosinophilia.

BACKGROUND: Angiolymphoid hyperplasia with eosinophilia (ALHE) is a benign and very rare skin disorder of uncertain etiology. It occurs in both dermal and subcutaneous forms, which are regarded as variants of the same condition. Clinically, it is characterised by solitary or multiple, red to brown cutaneous papules or nodules, usually located on the head and neck. ALHE occurs mainly in young to middle-aged adults, and more frequently affects women. CASE REPORT: A 36-year-old Caucasian woman with a one-year history of ALHE is presented. The diagnosis of this rare entity was based on the clinical and histological examination. CONCLUSIONS: Although there are many methods of treatment, the final result is not always satisfactory for patient. We present our case as a reminder that cryotherapy can be regarded as an easy, safe and successful method of treatment in some patients.

Adult↗

PubMed2003

52 kD Ro/SS-A localizes to punctate structures in the cytoplasm of epithelial cells.

Autoantibodies directed against 52 kD and 60 kD Ro/SS-A are frequently found in the sera of patients with lupus erythematosus and Sjögren's syndrome-related disorders. Their location in the cell is subject to continuous debate in literature. It has been postulated that 52 kD Ro (52 Ro) co-localizes with the 60 kD Ro autoantigen in the nucleus, while others demonstrated that 52 Ro is primarily cytoplasmic. In order to resolve this controversy, 52 Ro protein was tagged with green fluorescence protein, overexpressed in A431 keratynocytes, and its location determined using fluorescence confocal microscopy. The intracellular location of the fusion protein was revealed via GFP autofluorescene and indirect immunofluorescence microscopy, using purified anti-52 Ro antibodies. The cellular locations of native 52 Ro in normal human keratinocytes, and in human A431 keratinocyte and HepG2 hepatocyte cell lines were similarly determined by utilizing 2 human anti-52 Ro antibodies purified from two different non-overlapping fragments of recombinant 52 Ro. In addition, colocalization of 52 Ro with mitochondria, lysosomes and endosomes was evaluated. It was found that both the 52 Ro-GFP fusion protein and the native 52 Ro localize in discrete cytoplasmic punctate structures separately from the mitochondria, lysosomes and endosomes. Furthermore, human autoantibodies that are reactive with denaturation-sensitive epitopes on 52 Ro recognize these cytoplasmic punctate structures, whereas antibodies directed against denaturation-resistant 52 Ro epitopes do not. This explains why the previously used antibody against denaturation-resistant 52 Ro epitopes failed to detect the protein in such punctate structures.

Autoantigens↗

PubMed2003

[The methods of hyperhidrosis treatment].

Physiological sweating from cutaneous eccrine glands maintains normothermia and skin hydratation. Hyperhidrosis, a pathological condition caused by excessive secretion of the eccrine sweat glands, is divided into physiologic, symptomatic and idiopathic type. Contemporary methods of hyperhidrosis treatment, in particular botulinum toxin injections are discussed.

Botulinum Toxins, Type A↗

PubMed2002

[Antimalarials in lupus erythematosus treatment].

Antimalarial therapy is regarded as the most successful treatment for cutaneous and also some symptoms of systemic lupus erythematosus. Although these drugs have been known for decades, the precise mechanisms of their action is not completely defined. Continuous research provides insight into the pathogenic mechanism of the antimalarial responsive disorders and facilitates the development of better targeted therapies. There are presented some relevant, putative and possible mechanisms by which antimalarials provide benefit in lupus patients.

Antimalarials↗

PubMed2002

[Drug eruptions].

In the following paper, there have been discussed the mechanisms of reactions which may result from adverse drug effects. In particular, the paper shows a clinical picture of skin lesions and various dermatological entities in which drugs are triggering factors.

Drug Eruptions↗

PubMed2002

[Usefulness of ultraviolet radiation in dermatological treatment].

Ultraviolet radiation causes a complex cascade of changes resulting in suppression of immune reactions. The anti-inflammatory and immunosuppressive properties are widely used in treatment of many dermatoses. Currently applied phototherapy methods are presented in this paper. The knowledge of the UV mechanisms, phototherapy schedules, appropriate indications and restrictions allows to achieve better therapeutic results and decreases the risk of side effects.

Animals↗

PubMedDate not supplied

1-Methylnicotinamide: a potent anti-inflammatory agent of vitamin origin.

It has been found that 1-methylnicotinamide (MNA+), a metabolite of nicotinamide, possesses significant anti-inflammatory properties. MNA+ is chemically stable, non-toxic and well tolerated. MNA+ can be used to treat wide variety of diseases and disorders and the use of this compound provides certain advantages over the use of nicotinamide.

Administration, Topical↗